AX-8 Market Drug Insight

“AX-8 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about AX-8 for Chronic Refractory Cough (CRC) in the seven major markets. A detailed picture of the AX-8 for chronic refractory cough in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the AX-8 for chronic refractory cough. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AX-8 market forecast analysis for chronic refractory cough in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic refractory cough.

Drug Summary

AX-8, being developed by Axalbion, is a potent, selective transient receptor potential melastatin 8 (TRPM8) agonist, for the treatment of CC. TRPM8 is expressed in many of the sensory fibers innervating the upper airways and can treat RCC by counterbalancing CHS by decreasing or abolishing pathological coughing, and limiting or suppressing abnormal sensations associated with cough.

Activation of TRPM8-expressing fibers with AX-8 normalizes the upper airway sensitivity in CC patients, thereby decreasing coughing (antitussive effect), irritation of the throat (counterirritant effect), and normalizing the cough reflex.

Recently, Axalbion announced positive Phase II results from a proof-of-concept study of AX8 in patients with RCC or UCC. Based on these positive findings, Axalbion plans to initiate another Phase II study to examine the dose frequency of AX-8 in the treatment of RCC in the first quarter of 2023.

Besides developing AX-8 for RCC, Axalbion is also developing it for Dry Eye Syndrome.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the AX-8 description, mechanism of action, dosage and administration, research and development activities in chronic refractory cough.
• Elaborated details on AX-8 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AX-8 research and development activities in chronic refractory cough across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AX-8.
• The report contains forecasted sales of for chronic refractory cough till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic refractory cough.
• The report also features the SWOT analysis with analyst views for AX-8 in chronic refractory cough.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AX-8 Analytical Perspective by DelveInsight

In-depth AX-8 Market Assessment

This report provides a detailed market assessment of AX-8 for chronic refractory cough in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

AX-8 Clinical Assessment

The report provides the clinical trials information of AX-8 for chronic refractory cough covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for chronic refractory cough is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AX-8 dominance.
• Other emerging products for chronic refractory cough are expected to give tough market competition to AX-8 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AX-8 in chronic refractory cough.
• Our in-depth analysis of the forecasted sales data of AX-8 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AX-8 in chronic refractory cough.

Key Questions

• What is the product type, route of administration and mechanism of action of AX-8?
• What is the clinical trial status of the study related to AX-8 in chronic refractory cough and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AX-8 development?
• What are the key designations that have been granted to AX-8 for chronic refractory cough?
• What is the forecasted market scenario of AX-8 for chronic refractory cough?
• What are the forecasted sales of AX-8 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to AX-8 for chronic refractory cough?
• Which are the late-stage emerging therapies under development for the treatment of chronic refractory cough?